Khalid Alsulaiman Shared a New Study About Clinical Outcomes of Apixaban
Khalid Alsulaiman, Vice Chairman, Clinical Trial Management (CTM) at King Abdullah International Medical Research Center, shared a post on LinkedIn:
“Happy to share our new study titled: “*Evaluation of the Clinical Outcomes of Apixaban Use in Patients with Atrial Fibrillation and Uncontrolled Hypothyroidism: A Real-world Evidence*”, published in Clinical and Applied Thrombosis/Hemostasis.
In this study, we evaluated the effectiveness and safety of apixaban among patients with atrial fibrillation who also suffer from uncontrolled hypothyroidism. Our findings indicate that the use of apixaban in patients with AF and uncontrolled hypothyroidism was linked to higher rates of thrombosis and major bleeding compared to those without known hypothyroidism. These findings highlight the need for further research through larger prospective studies in this often-overlooked population.
We would like to thank all investigators who contributed to this project from the Saudi Critical Care Pharmacy Research (SCAPE) Platform, Saudi Society for Multidisciplinary Research Development and Education (SCAPE Society) and King Abdullah International Medical Research Center (كيمارك KAIMRC).”
Title: Evaluation of the Clinical Outcomes of Apixaban Use in Patients with Atrial Fibrillation and Uncontrolled Hypothyroidism: A Real-world Evidence
Authors: Khalid Al Sulaiman, Manal A Aljohani, Abdullah F Alharthi, Hisham A Badreldin, Mohammed Y Alzahrani, Rahaf A Alqahtani, Walaa A Alshahrani, Fatimah M Abudayah, Mohammad S Shawaqfeh, Ahmed A Alrashed, Alaa M Alenazi, Nouf S Alsagri, Mohammed Yahya Asiri, Zayed Asiri, Sulaiman Aljarallah, Yusuf M. Garwan, Lama S. Alfehaid, Abeer A. Alenazi, Tariq Aldebasi, Shmeylan Alharbi, Ahmed Aldemerdash, Amer Alzahrani, Ohoud Aljuhani
Read full article here.
Stay updated with Hemostasis Today.
-
Sep 29, 2025, 12:54Microfluidic Technology Uncovers Ongoing TTP Disease Activity
-
Sep 29, 2025, 12:43Advancing Thrombosis Research: MRI-Based Methodology for Studying Thrombus Resolution
-
Sep 29, 2025, 05:58Samwel Mikaye on Understanding, Diagnosing, and Managing Deep Venous Thrombosis (DVT)
-
Sep 28, 2025, 14:08Mary Cushman: Dr Warkentin Is a Giant in Hematology
-
Sep 28, 2025, 13:31Michael Makris Highlights Vaccine Misinformation and Its Risks
-
Sep 29, 2025, 12:33Allison Wheeler: Some Days I Love Science a Little Bit More
-
Sep 29, 2025, 06:23Yudi Hardianto and Colleagues Give a Review on Stroke Rehabilitation in LMICs
-
Sep 29, 2025, 04:42Wolfgang Miesbach on the Bi8 Study: A Novel FVIII-Mimetic Antibody Gene Therapy for Haemophilia A
-
Sep 29, 2025, 04:16Salvador Payán Pernía on Equity Challenges in Access to Gene Therapy for Hemoglobinopathies
-
Sep 29, 2025, 04:02Nicolas Gendron: A Very Nice Demonstration by The Authors - Coffee is Associated with Reduced Risk of VTE
-
Sep 29, 2025, 05:06Sue Bacon on the Importance of Addressing Hospital-Acquired DVT and PE
-
Sep 24, 2025, 11:06Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039
-
Sep 23, 2025, 06:40Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
-
Sep 22, 2025, 07:10Aspirin Beyond the Heart․ Targeting PI3K-Altered Colorectal Cancer
-
Sep 22, 2025, 06:04ClearPlasma: A New Filter Technology to Enhance Clot Stability in Donated Plasma
-
Sep 29, 2025, 07:02Kambua Manundu: We Walked to Protest the Countless Lives of Women We Have Lost to Post Partum Hemorrhage
-
Sep 29, 2025, 06:41Ouma Oluga Unveiled Plans to Make Sickle Cell Screening Mandatory in Kenya at 80th UN General Assembly
-
Sep 29, 2025, 04:51Nathan Connell on Breakthrough Gene Therapy Advancing Care for People with Hemophilia
-
Sep 29, 2025, 04:28Emmeran Hauser: Fantastic to See First Results of Our Work in Europe
-
Sep 28, 2025, 10:33Côme Bommier: Burnout Is Common Among Hematology Professionals